Content about Research

PITTSBURGH — Generic drug maker Mylan has entered an agreement with Hoffmann La Roche concerning its version of an oral chemotherapy drug.

Mylan announced Wednesday that it had entered a settlement and license agreement with Hoffmann La Roche resolving a patent infringement lawsuit over Xeloda (capecitabine) tablets, a drug used to treat breast and colorectal cancers that have spread to other parts of the body.

CHADDS FORD, Pa. — Profits for Endo Pharmaceutical Holdings rose to $54.6 million during second quarter 2011, up 6% from $51.5 million in second quarter 2010, the drug maker said.

Sales for the quarter were $607.5 million, compared with $396.5 million in second quarter 2010. Sales of branded drugs were $398.3 million, an 8% increase over last year, which the company attributed to better sales of the pain drug Opana ER and the joint pain drug Voltaren Gel.

NEW BRUNSWICK, N.J. — Drug maker Johnson & Johnson plans to file for regulatory approval for 11 new drugs between 2011 and 2015, the company said Thursday in relation to a meeting between J&J’s executive committee and investors.

SILVER SPRING, Md. — A Food and Drug Administration panel will discuss findings in a clinical trial that has raised concerns about the safety and efficacy of Abbott's cholesterol-lowering drug when it’s combined with similar drugs, according to an FDA announcement.

ARLINGTON, Va. — The Center for Healthcare Supply Chain Research, the research foundation of the Healthcare Distribution Management Association, on Tuesday released “Assessing the Impact of Risk Evaluation and Mitigation Strategies (REMS) Requirements on the Pharmaceutical Supply Chain,” the first comprehensive research study analyzing the impact of REMS programs across the healthcare supply chain.

NEW YORK — Healthcare market research firm IMS Health will buy privately held market research firm SDI Health, IMS said.

Terms of the transaction were not disclosed, but the deal would bring together two of the leading healthcare analytics companies. In terms of drug industry analytics, IMS focuses on drug sales and dispensed prescriptions, while SDI provides data on prescriptions written by physicians and other prescribers.

RESEARCH TRIANGLE PARK, N.C. Watson Pharmaceuticals biotech subsidiary Eden Biodesign has signed a manufacturing agreement with Dutch biotech company Crucell that will give Watson access to Crucell’s cell line technology, the two companies announced Wednesday.

Under the agreement, Eden will provide process development and current good manufacturing practice services using Crucell’s PER.C6 technology to licensees using the technology to develop vaccines and gene therapies.

BASEL, Switzerland Swiss drug maker Roche has bought the rights to an investigative treatment for hepatitis C, Roche said.

The company announced Thursday that it had purchased global development and commercialization rights to the drug RG7227/ITMN-191 (danoprevir) from InterMune for $175 million.

Roche said the drug had shown promise in preclinical and early clinical development. The two companies have been developing the drug since 2006.